Merck & Co has said it will not file its cholesterol drug anacetrapib with regulators, saying that trial results are not good enough for clinical filings. The news came in a brief statement, which ...

The approvals were based on positive results from EV-302, in which Padcev plus Keytruda resulted in statistically significant ...

Researchers at Penn Medicine conducted a pilot randomized controlled trial to test the hypothesis that an e-triage ...

Medicare Advantage is continuing to bulk up its lobbying efforts, with the Better Medicare Alliance finding itself among 10 ...

The Make America Healthy Again movement had a negative impact on pharmaceutical innovation and the corporations responsible for it.

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other cheap high dividend stocks. According to Deutsche Bank Wealth Management, the global ...

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical ...

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

While it may be reasonable for the Chancellor to change arbitrary targets, markets are not easily bamboozled by fiddling with definitions ...

After hours: 7:59:39 p.m. EST Loading Chart for MRK ...